Thymosin α1 treatment of chronic hepatitis B: Results of a phase III multicentre, randomized, double-blind and placebo-controlled study

Journal of Viral Hepatitis

Volumn 6, Issue 5, 1999, Pages 397-403

  Mutchnick, M G ^a,e   Lindsay, K L ^b   Schiff, E R ^c   Cummings, G D ^a   Appelman, H D ^d   Peleman, R R ^a   Silva, M ^c   Roach, K C ^c   Simmons, F ^b   Milstein, S ^b   Gordon, S C ^a   Ehrinpreis, M N ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

Chronic hepatitis B; Thymosin; Treatment

Indexed keywords

PLACEBO; THYMOSIN ALPHA1; ANTIVIRUS AGENT; DRUG DERIVATIVE; HEPATITIS B(E) ANTIGEN; IMMUNOLOGICAL ADJUVANT; THYMOSIN; VIRUS DNA;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; BLOOD; HEPATITIS B VIRUS; ISOLATION AND PURIFICATION; MIDDLE AGED; PHYSIOLOGY; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; THYMOSIN; TREATMENT OUTCOME;

EID: 0032585756     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.1999.00181.x     Document Type: Article

References (18)

1. McQuillan GM, Alter J, Everhart JE. Viral hepatitis. In: Everhart JE, ed. Digestive Diseases in the United States: Epidemiology and Impact. Washington, DC: US Department of Health and Human Services, Public Health Service, National Institutes of Health, US Government Printing Office, 1994: 125-156.
2. Lian YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8: 493-496.
3. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1993; 119: 312-323.
4. Carman WF, Thomas HC. Genetic variation in hepatitis B virus. Gastroenterology 1992; 102: 711-719.
5. Mills CT, Lee E, Perrillo R. Relationship between histology, aminotransferase levels, and viral replication in chronic hepatitis B. Gastroenterology 1990; 99: 519-524.
6. Lok ASF. Treatment of chronic hepatitis B. J Viral Hep 1994; 1: 105-124.
7. Mutchnick MG, Appelman HD, Chung HT et al. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology 1991; 14: 409-415.
8. 1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody - and hepatitis B virus DNA - positive chronic hepatitis B. Hepatology 1996; 24: 774-777.
9. 1 therapy in the treatment of chronic hepatitis B. J Viral Hep 1996; 3: 191-196.
10. 1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology 1998; 27: 1383-1387.
11. Farhat BA, Marinos G, Daniels HM, Naoumoo NV, Williams R. Evaluation of efficacy and safety of thymus humoral factor-gamma 2 in the management of chronic hepatitis B. J Hepatol 1995; 23: 21-27.
12. Naylor PH, Mutchnick MG. Thymus derived peptides in the treatment of viral chronic hepatitis. Dig Dis 1996; 14: 362-376.
13. 2 interferon treatment of HBsAg, HBeAb, HBV DNA positive chronic active hepatitis (abstr). Hepatology 1992; 16: 67A.
14. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histologic activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435.
15. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-374.
16. Zav'yalov VP, Denesyuk AI, Zav'yalova GA. Theoretical analysis of conformation and active sites of interferons. Immunol Lett 1989; 22: 173-181.
17. Mutchnick MG, Ehrinpreis MN, Kinzie JL, Peleman RR. Prospectives on the treatment of chronic hepatitis B and chronic hepatitis C with thymic peptides and antiviral agents. Antiviral Res 1994; 24: 245-257.
18. 1 in serum and supernatants by combining HPLC and RIA. Int J Immunopharm 1992; 14: 1267-1278.